June 2019 in “International journal of dermatology and venereology” A man developed skin issues from cancer medication, which improved with specific treatments.
7 citations
,
April 1996 in “Archives of dermatological research” Topical tacalcitol can treat psoriasis by acting directly on skin cells.
4 citations
,
August 2022 in “The Scientific World Journal” Merremia peltata leaf extract, particularly the bufotalinin compound, shows potential for treating hair loss.
January 2004 in “Headache” Divalproex sodium significantly improved headaches in two-thirds of patients.
1 citations
,
June 1999 in “American Journal of Contact Dermatitis” Tazarotene gel is more effective for acne than tretinoin and works as well as adapalene.
26 citations
,
January 1992 in “Carcinogenesis” TPA strongly increases ODC activity in certain skin cells, potentially aiding tumor growth.
42 citations
,
August 2012 in “Psychoneuroendocrinology” Finasteride reduces certain behaviors caused by D1-like receptor agonists but not by D2-like receptor agonists in mice.
18 citations
,
October 2017 in “Drug Design Development and Therapy” DA-9401 helps protect rat testis from finasteride damage.
July 2024 in “Journal of Investigative Dermatology” Topical melatonin may reduce skin aging by inhibiting certain cellular pathways.
3 citations
,
June 1987 in “British Journal of Dermatology” Nifedipine may help treat perniosis, improving symptoms and clearing lesions for some patients.
January 2025 in “Recent Patents on Anti-Cancer Drug Discovery” The treatment showed high response rates and was well-tolerated, potentially extending patient survival.
16 citations
,
June 2015 in “Drug Design Development and Therapy” The new formulation improves dutasteride's absorption when taken orally.
August 2017 in “Drug and Therapeutics Bulletin” Finasteride may cause depression, suicidal thoughts, and sexual side effects.
July 2024 in “Journal of Investigative Dermatology” A KLK5 inhibitor effectively improved skin symptoms in a mouse model of Netherton Syndrome.
1 citations
,
February 2023 in “Russian Journal of Bioorganic Chemistry” The new compound may be a safer alternative to finasteride for prostate protection.
December 2025 in “JMIR Dermatology” Topical finasteride is well-tolerated and satisfies most users with minimal side effects.
9 citations
,
December 2023 in “Journal of Neuroimmune Pharmacology” NDP-MSH protects brain cells and reduces inflammation in Parkinson's disease by activating MC1R and involving Tregs.
January 2025 in “Journal of Prescribing Practice” January 2021 in “Asian Journal of Research in Dermatological Science”
6 citations
,
April 2022 in “Biomedicine & pharmacotherapy” Using three different drugs together may better treat eye diseases like glaucoma and macular degeneration.
6 citations
,
April 2014 in “PubMed” A man got brown patches on his skin (melasma) after taking finasteride, a hair loss treatment.
January 1975 in “NJEA Review” The drug showed promise in treating renal cell carcinoma with manageable side effects.
September 2022 in “Journal of The American Academy of Dermatology” Combining dutasteride mesotherapy with oral minoxidil is more effective for hair loss than using oral minoxidil alone.
15 citations
,
June 2018 in “Life Sciences” Diabetex improves diabetic wound healing better than metformin.
February 2006 in “Inpharma Weekly”
December 2025 in “Molecules” DPP may help hair regrowth by improving blood vessel function under stress.
October 2015 in “Reactions Weekly” A woman got a scalp condition from using latanoprost, but it improved after stopping the drug and starting other treatments.
1 citations
,
January 2024 in “Curēus” Upadacitinib significantly improved a man's severe scalp condition when other treatments failed.
November 2020 in “International journal of pharmaceutical compounding” A stable and simple finasteride suspension was developed that retains over 94.3% of its concentration for up to 90 days and doesn't significantly increase occupational exposure, but safety measures are still advised.
44 citations
,
April 2006 in “Expert opinion on drug safety” Gefitinib can cause skin problems, diarrhea, and nausea, but rarely causes severe lung disease or hair loss.